StockMarketWire.com - ViiV Healthcare, a GlaxoSmithKline-Pfizer joint venture, said its injectable HIV treatment had met its primary goal in a clinical trial, reducing the number of treatments needed every year, compared to an oral treatment.

'The study met its primary endpoint, showing that the long-acting regimen of cabotegravir and rilpivirine, injected every two months, was non-inferior to cabotegravir and rilpivirine administered every month at Week 48,' the company said.

'The ATLAS-2M study results mean that people living with HIV could maintain viral suppression with six total treatments per year, instead of a daily oral treatment 365 times per year, it added.

The study was designed to demonstrate the non-inferior antiviral activity and safety of cabotegravir and rilpivirine administered every eight weeks (two months) compared to every four weeks (monthly) over a 48-week treatment period in adults living with HIV-1 infection, whose viral load was suppressed and who were not resistant to cabotegravir or rilpivirine.








Story provided by StockMarketWire.com